The clinical efficacy of lefamulin in the treatment of elderly patients with community-acquired bacterial pneumonia
Abstract
J Thorac Dis 2020;12(8):4588-4590 | http://dx.doi.org/10.21037/jtd-19-3805 Community-acquired bacterial pneumonia (CABP) remains a common cause of elderly patients requiring hospitalization and it can also be associated with significant morbidity and mortality (1-3). Common causative pathogens of CAPB include typical pathogens—Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis , and the atypical pathogens— Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila. Appropriate antibiotics are the key of successful management of elderly patients with CABP (2), however, the emergence of antimicrobial resistance among these respiratory pathogens limits the choice of antibiotic and could negatively impact the outcomes of the elderly patients with CAPB. Fortunately, recent development of a novel antibiotic— lefamulin, the first systemic pleuromutilin antibiotic, is active against the most common CABP-causing pathogens, including both typical and atypical pathogens and can provide us a therapeutic alternative in this clinical entity (4). In addition to in vitro studies (5,6), two phase III studies— Lefamulin Evaluation Against Pneumonia (LEAP) 1 trial (7) and LEAP 2 trial (8) have reported the clinical efficacy and safety profile of lefamulin for treating CABP. However, the usefulness of lefamulin in the elderly patients remains unclear. Therefore, we extracted the results of LEAP 1 and 2 trials (7,8) for the elderly…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 517 participants or records.
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.